Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of General Surgery, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Bioengineered. 2021 Dec;12(2):11533-11543. doi: 10.1080/21655979.2021.2009965.
The natural compound Hydroxysafflor yellow A (HSYA) has been demonstrated to exert anti-cancer effect on multiple cancers. This study aimed to clarify the role of HSYA in inhibiting colorectal cancer (CRC) in vitro and the underlying mechanisms. Different concentrations of HSYA (0, 25, 50, and 100 μM) was exposed to HCT116 CRC cells, then cell proliferation, apoptosis, migration, and invasion were estimated by colony formation assay, TUNEL staining, wound-healing, and transwell assays, respectively. Western blotting assay was utilized to observe the expression of proteins involved in cell apoptosis, migration, and peroxisome proliferator-activated receptor γ (PPARγ)/PTEN/Akt signaling, including PCNA, Bax, Bcl-2, cleaved-caspase3, E-cadherin, N-cadherin, vimentin, PPARγ, and phosphorylated (p)-Akt. HCT116 cells that treated with 100 μM HSYA were also pre-treated with PPARγ antagonist, GW9662, or knockdown with PPARγ using short hairpin (sh)-RNA, to down-regulate PPARγ expression. Then, the above functional analysis was repeated. Results demonstrated that HSYA (25, 50 and 100 μM) significantly reduced HCT116 cell viability, but had no effect on the cell viability of human normal intestinal epithelial cell HIEC. HSYA also inhibited colony formation, migration, and invasion but promoted apoptosis of HCT116 cell in a concentration-dependent manner. Besides, the PPARγ/PTEN/Akt signaling was activated upon HSYA treatment. Finally, GW9662 and PPARγ knockdown blocked all the effects of HSYA on HCT116 cells. In conclusion, HSYA could exhibit anti-cancer effect on CRC via activating PPARγ/PTEN/Akt signaling, thereby inhibiting cells proliferation, migration, and invasion in vitro.
天然化合物羟基红花黄色素 A(HSYA)已被证明对多种癌症具有抗癌作用。本研究旨在阐明 HSYA 在体外抑制结直肠癌(CRC)中的作用及其潜在机制。将不同浓度的 HSYA(0、25、50 和 100μM)暴露于 HCT116 CRC 细胞中,然后通过集落形成实验、TUNEL 染色、划痕愈合实验和 Transwell 实验分别评估细胞增殖、凋亡、迁移和侵袭。Western blot 实验用于观察细胞凋亡、迁移和过氧化物酶体增殖物激活受体 γ(PPARγ)/PTEN/Akt 信号通路中涉及的蛋白表达,包括 PCNA、Bax、Bcl-2、cleaved-caspase3、E-cadherin、N-cadherin、vimentin、PPARγ 和磷酸化(p)-Akt。用 100μM HSYA 处理的 HCT116 细胞还预先用 PPARγ 拮抗剂 GW9662 处理,或用短发夹(sh)-RNA 敲低 PPARγ,以下调 PPARγ 表达。然后,重复上述功能分析。结果表明,HSYA(25、50 和 100μM)显著降低 HCT116 细胞活力,但对人正常肠上皮细胞 HIEC 的细胞活力没有影响。HSYA 还呈浓度依赖性地抑制集落形成、迁移和侵袭,但促进 HCT116 细胞凋亡。此外,PPARγ/PTEN/Akt 信号通路在 HSYA 处理后被激活。最后,GW9662 和 PPARγ 敲低阻断了 HSYA 对 HCT116 细胞的所有作用。总之,HSYA 通过激活 PPARγ/PTEN/Akt 信号通路,在体外对 CRC 发挥抗癌作用,从而抑制细胞增殖、迁移和侵袭。